20th International AIDS Conference - Melbourne, Australia


WEAB01 Beyond Control of HIV: Co-morbidities and Co-infections around the World
  Oral Abstract Session : Track B
Venue: Melbourne Room 1
Time: 23.07.2014, 16:30 - 18:00
Co-Chairs: Andrew Carr, Australia
Quarraisha Abdool Karim, South Africa

16:30
WEAB0101
Abstract
Webcast
Efficacy of HPV vaccination in HIV+ adolescents and young adults for the induction of strong HPV-specific humoral and cell-mediated immune responses
V. Rainone1, D. Trabattoni1, F. Penagini2, V. Fabiano2, V. Giacomet2, A. Viganò2, M. Clerici3,4, G.V. Zuccotti2
1University of Milan, Department of Biomedical and Clinical Sciences L. Sacco, Milan, Italy, 2Luigi Sacco Hospital, Department of Pediatrics, Milan, Italy, 3University of Milan, Department of Physiopathology and Transplants, Milan, Italy, 4Don Carlo Gnocchi Foundation, Milan, Italy

16:32
WEAB0102
Abstract
Powerpoint
Webcast
Efficacy of HPV vaccination in HIV+ adolescents and young adults for the induction of strong HPV-specific humoral and cell-mediated immune responses
V. Rainone1, D. Trabattoni1, F. Penagini2, V. Fabiano2, V. Giacomet2, A. Viganò2, M. Clerici3,4, G.V. Zuccotti2
1University of Milan, Department of Biomedical and Clinical Sciences L. Sacco, Milan, Italy, 2Luigi Sacco Hospital, Department of Pediatrics, Milan, Italy, 3University of Milan, Department of Physiopathology and Transplants, Milan, Italy, 4Don Carlo Gnocchi Foundation, Milan, Italy

16:42
WEAB0103
Abstract
Incidence and clearance of anal high-grade squamous intraepithelial lesions (HSIL) in HIV positive and HIV negative homosexual men
A.E. Grulich1, F. Jin1, I.M. Poynten1, J. Roberts2, A. Farnsworth2, D.J. Templeton1,3, S.N. Tabrizi4, S.M. Garland4, C.K. Fairley5, R.J. Hillman6,7, the SPANC Study Team
1UNSW, Kirby Institute, Sydney, Australia, 2Douglass Hanly Moir Pathology, Sydney, Australia, 3Royal Prince Alfred Hospital, RPA Sexual Health, Sydney, Australia, 4University of Melbourne, Royal Women's Hospital, Melbourne, Australia, 5Melbourne Sexual Health Centre, Melbourne, Australia, 6University of Sydney, Western Sydney Sexual Health Centre, Sydney, Australia, 7St Vincent's Hospital, Sydney, Australia

16:54
WEAB0103
Abstract
Powerpoint
Webcast
Impact of short-term change in body mass index (BMI) after antiretroviral therapy (ART) initiation on subsequent risk of cardiovascular disease (CVD) and diabetes in HIV-positive individuals: the D:A:D study
A.C. Achhra1, A. Mocroft2, P. Reiss3, C. Sabin2, L. Ryom4, S. de Wit5, C. Smith2, A.D. Monforte6, A. Phillips2, R. Weber7, J. Lundgren8, M.G. Law1, The D:A:D Study Group
1Kirby Institute for Infection and Immunity in Society, Sydney, Australia, 2University College London, Infection & Population Health, London, United Kingdom, 3University of Amsterdam, Division of Infectious Diseases and Department of Global Health, Amsterdam, Netherlands, 4University of Copenhagen, Copenhagen, Denmark, 5Centre Hospitalier Universitaire Saint-Pierre, Brussels, Belgium, 6University of Milan Clinic of Infectious Diseases, Milan, Italy, 7University Hospital in Zurich, Zurich, Switzerland, 8Rigshospitalet & University of Copenhagen, Copenhagen, Denmark

17:06
WEAB0105
Abstract
Powerpoint
Webcast
Chronic obstructive pulmonary disease (COPD) in a large international cohort of HIV-infected adults with CD4+ counts >500 cells/mm3
K. Kunisaki1,2, D. Niewoehner1,2, G. Collins2, D. Nixon3, E. Tedaldi4, C. Akolo5, C. Kityo6, H. Klinker7, A. La Rosa8, J. Connett2, INSIGHT START Study Team
1Minneapolis VA Health Care System, Minneapolis, United States, 2University of Minnesota, Minneapolis, United States, 3Virginia Commonwealth University, Richmond, United States, 4Temple University, Philadelphia, United States, 5Institute of Human Virology Nigeria, Abuja, Nigeria, 6Joint Clinical Research Center, Kampala, Uganda, 7University of Wuerzburg, Wuerzburg, Germany, 8Asociacion Civil Impacta Salud y Educacion, Lima, Peru

17:18
WEAB0106
Abstract
Powerpoint
Webcast
HIV and cancer in referral hospitals from four West African countries, the IeDEA West Africa Collaboration
A. Jaquet1, M. Odutola2, D.K. Ekouevi1,3, A. Tanon4, E. Oga2, B.G. Kariyiare3, J. Akakpo5,6, M. Charurat2, M.D. Zannou5,6, S.P. Eholie4, A.J. Sasco1, E. Bissagnene4, C. Adebamowo2, F. Dabis1, the IeDEA West Africa Collaboration
1INSERM U 897, ISPED, Université de Bordeaux, Bordeaux, France, 2Institute of Human Virology of Nigeria (IHVN), Abuja, Nigeria, 3Université de Lomé, Département des Sciences Fondamentales et santé Publique, Faculté mixte de Médecine et de Pharmacie, Lomé, Togo, 4Service de Maladies Infectieuses et Tropicales (SMIT), CHU de Treichville, Abidjan, Cote D'Ivoire, 5Centre de Traitement Ambulatoire des Personnes Vivant avec le VIH (CTA/CHNU), Cotonou, Benin, 6Service de Médecine Interne et d'Oncologie, CNHU HKM, Cotonou, Benin

17:30
WEAB0107
Abstract
Powerpoint
Webcast
Comparison of effects of atazanavir, raltegravir, or darunavir with FTC/tenofovir on biomarkers of systemic inflammation, macrophage and T cell activation: ACTG A5260s
T. Kelesidis1, T.T.T. Tran2, G.A. McComsey3, T.T. Brown4, C. Moser2, H.J. Ribaudo2, J. Rothenberg5, O.O. Yang1, J.H. Stein6, J.S. Currier1
1David Geffen School of Medicine at UCLA, Los Angeles, United States, 2Harvard School of Public Health, Boston, United States, 3Case Western Reserve University, Cleveland, United States, 4Johns Hopkins University, Baltimore, United States, 5Social & Scientific Systems, Inc., Boston, United States, 6University of Wisconsin School of Medicine and Public Health, Madison, United States

17:45
WEAB0107
Webcast
Moderated discussion

Powerpoints presentations
Efficacy of HPV vaccination in HIV+ adolescents and young adults for the induction of strong HPV-specific humoral and cell-mediated immune responses -

Impact of short-term change in body mass index (BMI) after antiretroviral therapy (ART) initiation on subsequent risk of cardiovascular disease (CVD) and diabetes in HIV-positive individuals: the D:A:D study - Amit C Achhra

Chronic obstructive pulmonary disease (COPD) in a large international cohort of HIV-infected adults with CD4+ counts >500 cells/mm3 - Ken Kunisaki

HIV and cancer in referral hospitals from four West African countries, the IeDEA West Africa Collaboration - Antoine Jaquet

Comparison of effects of atazanavir, raltegravir, or darunavir with FTC/tenofovir on biomarkers of systemic inflammation, macrophage and T cell activation: ACTG A5260s - Theodoros Kelesidis



Rapporteur report

Track B report by Mark Bloch


In this session, Veronica Rainone described the findings of Protocol NCT01512784, an Italian study which examined the immunogenicity of 3 standard doses of the quadrivalent HPV vaccine (Gardisil) in HIV positive and negative adolescents and found similar antibody and CMI responses.

Andrew Grulich  outlined the interim findings of the SPANC study which is a natural history anal HPV study in HIV positive and HIV negative MSM. The study had a composite end point of histology and cytological HSIL 450 men were enrolled by June 2014, median age 49yrs, 31% HIV. Baseline HSIL prevalence was 46% in HIV and 34% in HIV negatives. In those free of HSIL at baseline, rates of progression  incidence was 16/100 py. The study also found spontaneous clearance rate 42/100 py.

 

Amit Achhra examined  D:A:D short term ART initiation, which is associated wtih weight gain, and development of CVD and diabetes. There were approximately 9000 patients who had initiated ART with 1 year follow up and BMI. Baseline low BMI increased 2.55, normal 1.38, overweight and obese to a lesser extent over 1 year. Adjusted CVD increased especially with normal BMI and diabetes mellitus increased 11%.

 

Ken Kuniaski reported on COPD which was asssessed in a sub-study of the START trial. He examined those with HIV CD4>500.

In the START pulmonary substudy  prevalence of COPD was 6.8%  but this increased to 12% in current smokers and 9.2% in those >44yrs of age.

 

Antoine Jaquet described a survey of cancer in 4 West African countries from hospital diagnoses over 12 months in HIV positive and negative patients. In HIV negatives, commonest cancers were breast, cervix and prostate. In HIV positives commonest were cervical, KS and non Hodgkin’s lymphoma (NHL). Odds Ratio in HIV for KS was 32.2, NHL 3.8, and for non AIDS cancers, anal/vulvar/vaginal 17.7 and SCC 5.8.

 

Theodoros Kelesidis gave results of ACTG A5260s (substudy of ACTG 5257)which examined biomarkers of systemic inflammation and immune activation with ATV/r, DRV/r, raltegravir, all with truvada.

Over 96weeks raltegravir did not have differential effects on systemic inflammation and immune activation compared to protease inhibitors.


   

    The organizers reserve the right to amend the programme.